Modifications to a type of immune cell programmed to recognize and kill cancerous tumors could make them even more effective ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 ...

An international team of researchers reports that the immune cells of older adults with a history of endurance training are more effective at combating inflammation. Regular physical activity not only ...

Leukon Therapeutics, Inc., a San Diego-based clinical-stage biotechnology company developing next-generation mRNA-based immunotherapies, today announced that the U.S. Food and Drug Administration (FDA ...

Stockholm – November 3, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that a collaborative study within the Eurostars ...

ANKL is a rare and aggressive type of blood cancer affecting a type of white blood cell called natural killer (NK) cells. In ANKL, the NK cells are abnormal and multiply out of control, crowding out ...

The latest update is out from Oncopeptides AB ( (SE:ONCO) ).

MIT and Harvard scientists have designed an advanced type of immune cell called a CAR-NK cell that can destroy cancer while avoiding attack from the body’s own immune defenses. This innovation could ...